Traditionally, the development of small-molecule inhibitors requires high throughput screening of a large library of diverse drug-like compounds or a medicinal chemist iterating over a scaffold with weak receptor activity to enhance potency. This entire process is -(i) time consuming; (ii) needs expensive instrumentation and robotics; (iii) based on trial-and-error; and